Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Sees Large Growth in Short Interest

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 2,126 shares, an increase of 38.7% from the February 12th total of 1,533 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 4,451 shares, the short-interest ratio is presently 0.5 days. Based on an average trading volume of 4,451 shares, the short-interest ratio is presently 0.5 days. Approximately 0.1% of the shares of the stock are short sold.

Invesco Biotechnology & Genome ETF Stock Performance

PBE remained flat at $76.18 on Friday. The company had a trading volume of 22,805 shares, compared to its average volume of 7,357. The firm has a 50 day simple moving average of $81.70 and a 200 day simple moving average of $77.78. The company has a market capitalization of $244.54 million, a price-to-earnings ratio of 20.44 and a beta of 0.79. Invesco Biotechnology & Genome ETF has a 52 week low of $54.52 and a 52 week high of $85.73.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

Institutional investors and hedge funds have recently modified their holdings of the stock. Gerber Kawasaki Wealth & Investment Management lifted its stake in Invesco Biotechnology & Genome ETF by 4.2% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 254,172 shares of the company’s stock worth $16,292,000 after purchasing an additional 10,213 shares in the last quarter. Allworth Financial LP bought a new position in shares of Invesco Biotechnology & Genome ETF during the 2nd quarter valued at about $54,000. RFG Advisory LLC grew its position in shares of Invesco Biotechnology & Genome ETF by 6.6% during the fourth quarter. RFG Advisory LLC now owns 8,455 shares of the company’s stock valued at $695,000 after purchasing an additional 521 shares in the last quarter. Q3 Asset Management purchased a new position in shares of Invesco Biotechnology & Genome ETF during the fourth quarter valued at about $1,431,000. Finally, Stratos Wealth Partners LTD. bought a new stake in shares of Invesco Biotechnology & Genome ETF in the fourth quarter worth about $260,000.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.